title: Prognostic value of raf kinase inhibitor protein in esophageal squamous cell carcinoma.
abstract: Raf kinase inhibitory protein (RKIP, also PEBP1) is involved in regulation of multiple cellular signaling processes and suppressing metastasis in animal models. Downregulation of RKIP expression has been shown to promote tumor progression in a variety of human cancers. However, its role and clinical significance in resectable esophageal squamous cell carcinoma (ESCC) is still scanty. The purpose of this study was to investigate the prognostic significance of RKIP expression by immunohistochemistry in a group of patients with ESCC treated with surgical resection. RKIP expression in 233 surgically resected ESCC specimens and 49 cases of adjacent normal tissues was detected by using immunohistochemical staining. The clinical and prognostic significance of RKIP expression was statistically analyzed. Kaplan-Meier analysis was used to compare the postoperative survival between groups. Significant downregulation was noted for RKIP protein in ESCCs, compared to adjacent normal tissues (p < 0.001). A lower disease-free survival and overall survival of ESCC was found in patients whose tissues had low RKIP expression (both P < 0.001). In addition, RKIP expression could stratify the patient survival (disease-free survival/overall survival) in stage II (P = 0.01 and 0.02, repectively). The Cox proportionate hazard regression model also established that low expression of RKIP was significantly correlated with increased risk (RR = 3.572) of recurrence compared with high RKIP expression (P < 0.001). Furthermore, the results of multivariate analysis suggested that RKIP expression (P < 0.001) was an independent factor that affected overall survival. These findings suggest that the low expression of RKIP be associated with poor survival in resectable ESCC patients.
authors.affiliation: Department of Gastroenterology, Huai'an No.1 Hospital, Affiliated to Nanjing Medical University, Huai'an, Jiangsu, 223300, China.
authors.forename: Chengcheng
authors.initials: C
authors.lastname: Gao
authors.forename: Liqun
authors.initials: L
authors.lastname: Pang
authors.forename: Chengcheng
authors.initials: C
authors.lastname: Ren
authors.forename: Tianheng
authors.initials: T
authors.lastname: Ma
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000378:metabolism*; D002294:Carcinoma, Squamous Cell / Q000378:metabolism* / Q000401:mortality / Q000601:surgery; D004938:Esophageal Neoplasms / Q000378:metabolism* / Q000401:mortality / Q000601:surgery; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007124:Immunoenzyme Techniques; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000378:metabolism* / Q000401:mortality / Q000601:surgery; D009367:Neoplasm Staging; D049488:Phosphatidylethanolamine Binding Protein / Q000378:metabolism*; D011379:Prognosis; D015996:Survival Rate
chemical_list: D014408:Biomarkers, Tumor; C511482:PEBP1 protein, human; D049488:Phosphatidylethanolamine Binding Protein
references.citation: Pathol Oncol Res. 2011 Jun;17(2):181-90
references.pmid: 20853079
references.citation: CA Cancer J Clin. 1999 Jan-Feb;49(1):8-31, 1
references.pmid: 10200775
references.citation: J Hepatol. 2010 Nov;53(5):872-9
references.pmid: 20739083
references.citation: Gynecol Oncol. 2008 Mar;108(3):520-6
references.pmid: 18191186
references.citation: Anticancer Drugs. 2004 Aug;15(7):663-9
references.pmid: 15269597
references.citation: Biochim Biophys Acta. 1984 Oct 23;790(2):174-81
references.pmid: 6435678
references.citation: Crit Rev Immunol. 2009;29(3):241-54
references.pmid: 19538137
references.citation: Med Res Rev. 2012 Sep;32(5):1026-77
references.pmid: 22886631
references.citation: Am J Clin Pathol. 2007 May;127(5):820-7
references.pmid: 17439843
references.citation: Dis Esophagus. 2012 Jan;25(1):67-71
references.pmid: 21689205
references.citation: J Clin Pathol. 2008 Apr;61(4):524-9
references.pmid: 18375747
references.citation: Hepatogastroenterology. 2011 Mar-Apr;58(106):426-31
references.pmid: 21661408
references.citation: Mol Cancer Res. 2009 Jun;7(6):832-40
references.pmid: 19531568
references.citation: Ann Surg Oncol. 2010 Jul;17(7):1721-4
references.pmid: 20369299
references.citation: Med Oncol. 2010 Jun;27(2):219-23
references.pmid: 19291429
references.citation: Cell Res. 2005 Jan;15(1):19-23
references.pmid: 15686621
references.citation: J Immunol. 2007 Oct 15;179(8):5441-53
references.pmid: 17911631
references.citation: Biochem Pharmacol. 2004 Sep 15;68(6):1049-53
references.pmid: 15313400
references.citation: J Cell Biochem. 2010 Jul 1;110(4):975-81
references.pmid: 20564197
references.citation: Oncogene. 2005 May 12;24(21):3535-40
references.pmid: 15782137
references.citation: J Natl Cancer Inst. 2003 Jun 18;95(12):878-89
references.pmid: 12813171
references.citation: Clin Cancer Res. 2005 Oct 15;11(20):7392-7
references.pmid: 16243812
references.citation: Crit Rev Immunol. 2010;30(1):31-46
references.pmid: 20370618
references.citation: Gastroenterology. 2006 Oct;131(4):1208-17
references.pmid: 17030190